INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
about
Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intoleranceEmerging drugs for chronic myeloid leukemia.Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomasInitial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing programLyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).A clinically relevant pharmacokinetic interaction between cyclosporine and imatinibEssential Role of Lyn in Fibrosis.Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Treatment of chronic myeloid leukemia when imatinib fails.Chronic myeloid leukemia stem cells and developing therapies.Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.Targeting Lyn regulates Snail family shuttling and inhibits metastasis.Chronic myeloid leukemia – some topical issues
P2860
Q30836557-DC7FECA1-B65B-42DB-9EDC-32C2FA561915Q33388870-F457CCCC-2AB8-40EC-AA03-1BC83BF3F492Q33536762-2908A966-CDA2-402E-A26A-6796ACA04F42Q33996893-AE606E25-8354-435E-B85B-2BAB7DC1CF6AQ34231554-34012E1D-183D-4F7B-9332-661F514B35D9Q35005309-901492D5-3681-478E-BC46-4A2711FC2A97Q35832402-959B580D-7F03-4245-AEF2-564422629ECDQ36822880-8D62ABC3-B4D8-4938-A071-C0F71575037FQ36897027-4A9A54D9-791F-484E-85E0-3CA9D47DEE84Q37221535-BF47610C-B5D2-4044-8F74-FAE96A5BD95EQ37256808-DDBDB336-E3C2-41E5-8F9F-5726CA211F69Q37574957-115AD154-E9D0-4F10-BF8A-0B111DE89E65Q37657488-A76978D5-8FFD-4BC8-85D0-BC325F661790Q37663655-6360DDF8-EDF5-4398-B890-F55EF3446CEBQ37827875-2D904AE8-3516-4067-BA73-8787EFEB5AB6Q37836936-5001DBF8-070C-4D58-90B5-A695AF6F1AE3Q37889508-E18B7A63-3498-403C-9DBF-7E4EF6853E2FQ38187646-D40A06DA-E67E-4528-AEE3-7788F516C771Q39694428-0B4DFFB5-802D-476B-AD5C-909F0C00ABE4Q39984274-0F69AF11-9F64-4099-B96A-24A539934A7DQ40131183-B658D4DF-4A95-49FF-AD5A-DD8653BBBCACQ41168634-66CAEF1C-76F4-4D3C-98F3-067BADCC2E43Q43078241-592006DB-CB06-4198-8E86-59D09724ABC6Q43248374-4D6907D4-9289-4EEC-8BA1-5C8EA4A9C589Q47124745-9C05A0F0-7B03-4B92-BCC7-256F796958DBQ48274819-827D0C9B-8243-4D5E-B767-D2D9394F188DQ49151446-37F44B0F-3D16-4FBF-A9A2-FF1800EDC253Q50847430-599D7EF9-0A49-467B-ACAC-0FC0FDFAA9E1Q57902808-38C6E6BF-3AF3-4FB9-A6BF-D56222EFDA56
P2860
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity.
@en
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity.
@nl
type
label
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity.
@en
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity.
@nl
prefLabel
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity.
@en
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity.
@nl
P2093
P1433
P1476
INNO-406, a novel BCR-ABL/Lyn ...... augments its in vivo activity
@en
P2093
Asumi Yokota
Eishi Ashihara
Eri Kawata
Junya Kuroda
Ken-ichi Inui
Kiyohiko Hatake
Kiyoshi Sato
Satohiro Masuda
Shinya Kimura
Taira Maekawa
P304
P356
10.1182/BLOOD-2006-03-013250
P407
P50
P577
2006-09-05T00:00:00Z